Thiol/Disulphide Homeostasis and Albumin in Vertigo

Study Overview
=================
Brief Summary
-----------------
Vertigo is a common complaint in the Emergency Department (ED). The differential diagnosis of central and peripheral vertigo is a difficult issue that directly affects mortality. Magnetic resonance imaging (MRI) is the preferred diagnostic tool, but may not be suitable in all patients due to logistic and economic conditions. In this study, the investigators evaluated the role of thiol/disulfide homeostasis (TDH) parameters and ischemia modified albumin (IMA) levels to assist in the value of being used instead of MRI.

Detailed Description
-----------------
The study was conducted in the ED using a prospective, non-randomized method, and included patients with complaints of acute onset vertigo over 18 years of age and who underwent brain MRI. Pregnant women, smokers, and those with significant neurological signs were excluded. Patients with acute ischemia with MRI were included in the central vertigo group, and patients with normal MRI were included in the peripheral vertigo group. Blood samples for native thiol (NT), total thiol (TT), disulfide, and IMA were collected from all patients at admission. Statistical analyzes were performed with IBM SPSS Statistics for Windows 16.0 Package Program.

Official Title
-----------------
Evaluation of Thiol/Disulfide Homeostasis and Ischemia Modified Albumin Levels in the Differential Diagnosis of Central and Peripheral Vertigo

Conditions
-----------------
Vertigo, Peripheral, Vertigo, Central Origin, Oxidative Stress, Diagnosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with complaint of vertigo Patients over18 years of age Exclusion Criteria: Patients contraindicated for MRI due to metal prosthesis or claustrophobia Patients under 18 years of age Pregnant patients Tobacco users Patients exhibiting significant neurological signs or symptoms such as motor or sensory neurologic deficit, speech disorders, unconsciousness, or seizure Patients found to have any type of lesion such as a hematoma, mass, cyst, aneurysm, arteriovenous malformation, etc. other than ischemic infarcts on MRI Patients with an ischemic lesion other than posterior fossa lesions Patients with any type of infection, including upper respiratory tract and ear infections Patients previously diagnosed with peripheral vertigo Patients where the cause of lightheadedness was blood pressure disorders, cardiac ischemic and arrhythmic disorders, thromboembolic diseases, metabolic disorders, trauma, etc. rather than central and peripheral vertigo.

Ages Eligible for Study
-----------------
Minimum Age: 51 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Central vertigo<br>Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group. | |
| Peripheral vertigo<br>Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxidative stress | Thiol/disulphide homeostasis | 6 months | 
| Ischemic status | Ischemia modified albumin | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vertigo, Central vertigo, Peripheral vertigo, Thiol/disulfide homeostasis, Ischemia modified albumin, Differential diagnosis